Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study (Q34340390)

1 August 2017

title

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study (English)

1 reference

1 August 2017

6

A Le Cesne

0 references

Jean-Yves Blay

5

object named as

J-Y Blay

0 references

author name string

S Sleijfer

1

1 reference

1 August 2017

T Gorlia

2

1 reference

1 August 2017

C Lamers

3

1 reference

1 August 2017

H Burger

4

1 reference

1 August 2017

M Scurr

7

1 reference

1 August 2017

F Collin

8

1 reference

1 August 2017

L Pandite

9

1 reference

1 August 2017

S Marreaud

10

1 reference

1 August 2017

P Hohenberger

11

1 reference

1 August 2017

language of work or name

English

0 references

publication date

17 July 2012

1 reference

British Journal of Cancer

1 August 2017

published in

1 reference

1 August 2017

volume

107

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

639-645

1 reference

Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials

6 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.328

Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.328

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.328

A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.328

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.328

21 January 2018

Identifiers

DOI

10.1038/BJC.2012.328

1 reference

Dimensions Publication ID

1 August 2017

0 references

1 reference

1 August 2017

1 reference